drugset / Trial / NCT00479700

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects

NCT00479700

Phase 1 Completed 80 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of ascending single oral doses of SAM-531 in healthy subjects.To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-531, an investigational drug, in healthy subjects and to evaluate the effect of a high-fat meal on the PK of SAM-531 administered to healthy subjects.

Timeline

Start
2006-05
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule Oral

Indications